- Home
- CANG vs EYPT Comparison
CANG vs EYPT Comparison
Compare CANG & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- EYPT
- Stock Information
- Founded
- CANG 2010
- EYPT 1987
- Country
- CANG China
- EYPT United States
- Employees
- CANG N/A
- EYPT N/A
- Industry
- CANG Computer Software: Prepackaged Software
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CANG Technology
- EYPT Industrials
- Exchange
- CANG Nasdaq
- EYPT Nasdaq
- Market Cap
- CANG 525.0M
- EYPT 594.5M
- IPO Year
- CANG 2018
- EYPT 2005
- Fundamental
- Price
- CANG $4.60
- EYPT $7.63
- Analyst Decision
- CANG
- EYPT Strong Buy
- Analyst Count
- CANG 0
- EYPT 8
- Target Price
- CANG N/A
- EYPT $25.71
- AVG Volume (30 Days)
- CANG 1.2M
- EYPT 890.7K
- Earning Date
- CANG 03-10-2025
- EYPT 03-06-2025
- Dividend Yield
- CANG N/A
- EYPT N/A
- EPS Growth
- CANG N/A
- EYPT N/A
- EPS
- CANG 0.19
- EYPT N/A
- Revenue
- CANG $38,020,222.00
- EYPT $45,713,000.00
- Revenue This Year
- CANG $253.48
- EYPT N/A
- Revenue Next Year
- CANG N/A
- EYPT N/A
- P/E Ratio
- CANG $24.32
- EYPT N/A
- Revenue Growth
- CANG N/A
- EYPT 7.50
- 52 Week Low
- CANG $1.09
- EYPT $6.90
- 52 Week High
- CANG $9.66
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- CANG 48.91
- EYPT 46.11
- Support Level
- CANG $4.31
- EYPT $7.15
- Resistance Level
- CANG $4.72
- EYPT $8.25
- Average True Range (ATR)
- CANG 0.41
- EYPT 0.64
- MACD
- CANG -0.10
- EYPT -0.01
- Stochastic Oscillator
- CANG 28.26
- EYPT 27.80
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.